Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera by Pouw, R.B. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/202685
 
 
 
Please be advised that this information was generated on 2020-09-10 and may be subject to
change.
REGULAR ARTICLE
Potentiation of complement regulator factor H protects human endothelial
cells from complement attack in aHUS sera
Richard B. Pouw,1,2 Mieke C. Brouwer,1 Marlon de Gast,1 Anna E. van Beek,1,2 Lambertus P. van den Heuvel,3,4 Christoph Q. Schmidt,5
Arie van der Ende,6 Pilar Sa´nchez-Corral,7 Taco W. Kuijpers,2,8 and Diana Wouters1
1Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; 2Department of
Pediatric Hematology, Immunology and Infectious Diseases, Emma Children’s Hospital, Amsterdam UMC, Amsterdam, The Netherlands; 3Laboratory of Pediatric Nephrology,
Department of Development and Regeneration, Katholieke Universiteit Leuven, Leuven, Belgium; 4Department of Pediatric Nephrology, Radboud University Medical Center,
Nijmegen, The Netherlands; 5Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany; 6Department of Medical Microbiology,
Netherlands Reference Laboratory for Bacterial Meningitis, Center for Infection and Immunity Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The
Netherlands; 7Complement Research Group, Hospital La Paz Institute for Health Research, La Paz University Hospital, and Centre for Biomedical Network Research on Rare
Diseases, Madrid, Spain; and 8Department of Blood Cell Research, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam,
The Netherlands
Key Points
•Complement regulator
FH function can be
enhanced with an mAb
against domain 18.
• Potentiation of FH
function in aHUS sera
specifically restores
complement regulation
on human endothelial
cells.
Mutations in the gene encoding for complement regulator factor H (FH) severely disrupt its
normal function to protect human cells from unwanted complement activation, resulting in
diseases such as atypical hemolytic uremic syndrome (aHUS). aHUS presents with severe
hemolytic anemia, thrombocytopenia, and renal disease, leading to end-stage renal failure.
Treatment of severe complement-mediated disease, such as aHUS, by inhibiting the terminal
complement pathway, has proven to be successful but at the same time fails to preserve the
protective role of complement against pathogens. To improve complement regulation on
human cells without interfering with antimicrobial activity, we identified an anti-FH
monoclonalantibody (mAb) that induced increasedFH-mediatedprotectionofprimaryhuman
endothelial cells from complement, while preserving the complement-mediated killing of
bacteria.Moreover, this FH-activatingmAbrestored complement regulation in sera fromaHUS
patients carrying various heterozygous mutations in FH known to impair FH function and
dysregulatecomplementactivation.Ourdatasuggest thatFHnormallycirculates ina lessactive
conformation and can become more active, allowing enhanced complement regulation on
humancells. Antibody-mediated potentiation of FHmay serve as a highly effective approach to
inhibit unwanted complement activation on human cells in a wide range of hematological
diseases while preserving the protective role of complement against pathogens.
Introduction
The complement system is crucial in the defense against pathogens but, when not properly regulated,
can seriously damage human cells.1 Complement targets foreign surfaces either via pattern recognition
molecules, such as C1q and MBL, or through spontaneous activation of complement C3. This latter
pathway is called the alternative pathway (AP) and occurs on any surface due to the indiscriminate
covalent binding of activated C3 (C3b) to any surface in close proximity. Deposited C3b will again
initiate the AP, thereby forming an important amplification loop within the complement cascade. While
this is beneficial for targeting foreign surfaces, the AP also targets human cells. To prevent complement-
mediated damage, various complement regulators protect human cells by interrupting the cascade at
different steps. One of the most important regulators is complement factor H (FH).
Submitted 5 September 2018; accepted 24 January 2019. DOI 10.1182/
bloodadvances.2018025692.
The full-text version of this article contains a data supplement.
© 2019 by The American Society of Hematology
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FH is a 155-kDa glycoprotein circulating in plasma, consisting of
20 complement control protein (CCP) domains. The structure of FH
remains elusive, but it seems to circulate in different conformations or as
a monomeric protein folded back onto itself.2-4 Conformational changes
in FH are suggested to play a role in its function, with the central
domains of FH forming a loop that brings together the relatively distant
C3b-binding sites in its N- and C-terminal domains.5,6 The presence of
a latent, less active conformation of FH has been suggested as an
additional mechanism to avoid protecting foreign surfaces that do not
activate FH, while human cells are thought to fully activate FH.7 FH
inhibits the AP by binding to C3b, both in fluid phase and deposited
on human cells and tissues, blocking further complement activation
through competition with complement factor B for C3b binding.8-10
Furthermore, FH is a cofactor for complement factor I (FI), which
degrades C3b into inactive C3b (iC3b). FH protects human cells and it
distinguishes human from foreign surfaces by recognizing, next to C3b,
polyanionic residues that are specific for human cells.11-15
Impaired regulation of complement on human surfaces leads to severe
inflammatory disease like atypical hemolytic uremic syndrome (aHUS).
In aHUS, the imbalance in complement regulation and activation leads
to complement deposition on human cells, particularly in the kidneys,
causing severe vascular injury and end-stage renal failure.16-21 FH
function is impaired in 20% to 30% of aHUS patients due to
heterozygous mutations or autoantibodies.22 While aHUS-associated
FHmutations are found along the entire protein, theC-terminal CCP20
domain seems to be a hotspot for mutations and the target of most
autoantibodies,17,23 affecting the binding of FH toC3b and polyanionic
residues.18 Eculizumab is a nondepleting therapeutic monoclonal
antibody (mAb) targeting complement C5 and was approved for
the treatment of aHUS in 2011.24 It inhibits formation of the lytic
membrane attack complex. Thereby, eculizumab not only protects
human cells but also inhibits complement-mediated lysis of pathogens.
As genetic C5 deficiencies are associated with an increased risk of
Neisseria meningitidis infections,25 patients treated with eculizumab
are vaccinated against N meningitidis. New therapeutic approaches
acting upstream in the complement cascade are being explored while
preferably preserving complement-facilitated pathogen clearance.26-28
Because FH plays a crucial role in the regulation of complement
on human cells, we investigated the possibility of enhancing FH
activity to improve complement regulation on human cells. We have
generated anti-human FH mAbs and tested their effect on the
complement regulatory activity of FH. Although most mAbs inhibited
FH function, one mAb enhanced FH activity, resulting in more
efficient complement regulation on human cells. Our results support
the hypothesis that FH circulates in a less active conformation and its
activity can be increased. Because complement-mediated lysis of
bacteria was unaffected by our FH-potentiating mAb, we believe that
enhancing FH activity is of great interest as a safe alternative to the
current therapeutic interventions in complement-mediated diseases.
Methods
Patients and controls
All sera were obtained with informed consent according to the local
ethics committees in accordance with the Declaration of Helsinki.
Sera were from 2 Dutch aHUS patients (aHUS#1 and aHUS#2)
and 9 patients from the Spanish aHUS registry (aHUS#3-aHUS#11)
carrying different CFH variants. Functional data for Arg53Ser29
(aHUS#7), Ser411Thr30 (aHUS#10, also carrying a CFHR1::CFH
hybrid gene), Val1007Leu31 (aHUS#5), Trp1157Arg32 (aHUS#6),
Arg1182Lys29 (aHUS#8), Trp1183Leu33 (aHUS#3), Ser1191Leu34
(aHUS#1), and Val1197Ala18 (aHUS#9) mutations were described
previously. The functional consequences of Val383Ala (aHUS#11),
Glu847Val22 (aHUS#4), and Tyr1058His (aHUS#2) are unknown.
Normal human serum (NHS) pool contained sera of 30 healthy
donors, aliquoted and stored at 280°C. NHS was heat inactivated
(HI) by incubating the NHS pool at 56°C for 1 hour while shaking. The
NHS pool deficient in FHR-1 (CFHR12/2 pool) contained sera from
4 healthy donors without CFHR3 and CFHR1 genes (previously
determined by multiplex ligation–dependent probe amplification35).
FH-depleted serum was generated by affinity purification of FH using
anti-FH.16-coupled sepharose and collection of the flow through.
Materials and reagents
Plasma-derived human FH, FI, C3b, iC3b, and C3d were purchased
from CompTech. In-house–generated mouse mAbs directed against
interleukin-6 (IL-6) (immunoglobulin G1 [IgG1]) and factor XII (IgG2a)
were used as isotype controls. Eculizumab (Alexion Pharmaceutical) was
obtained by collecting surplus from used Soliris injection bottles. Sheep
erythrocytes (ES) were from Ha˚tunalab. Rabbit erythrocytes (ER) were
from Envigo. High-performance enzyme-linked immunosorbent assay
(ELISA) buffer (HPE), streptavidin conjugated with poly–horseradish
peroxidase (strep-poly-HRP), and rat anti-mouse k mAb (RM-19)
were from Sanquin Reagents.
Immunization and antibody characterization
Mouse immunization and generation and characterization of mAbs were
performed as described previously35 using plasma-derived human FH
as immunogen. Epitope mapping of anti-FH.07 was performed using
recombinant human FH fragments composed of multiple CCP domains as
indicated. In short, 5 mg anti-FH.07 was captured with 1 mg RM-
19–coupled sepharose and incubated overnight with 100 mL (4 3 104
counts/minute) 125I-labeled FH or FH fragments in phosphate-buffered
saline (PBS) with 0.1% (wt/vol) Tween-20 and 0.1% (wt/vol) bovine serum
albumin (BSA). Unbound FH fragments were washed 5 times with PBS
with0.1%(wt/vol) Tween-20.Sepharose-bound radioactivitywasmeasured
by counting for 30 seconds and corrected for total input (set to 100%).
A competitive ELISA was used to confirm the epitope mapping. Anti-
FH.07 was captured on a RM-19–coated microtiter plate to assure
optimal binding conformation. Next, biotinylated FH, with a 100-fold
higher concentration of the indicated unlabeled recombinant FH
fragments, was incubated on the plate for 1 hour. Binding of
biotinylated FH was determined using strep-poly-HRP. The ELISA
was developed using 100 mg/mL 3,5,39,59-tetramethylbenzidine in
0.1 M sodium acetate containing 0.003% (vol/vol) H2O2, pH 5.5,
stopped with 100 mL H2SO4 and absorbance was measured at
OD450nm and corrected for the absorbance at OD540nm with a
Synergy 2 Multi-Mode plate reader (BioTek Instruments). All steps
were performed using 100 mL per well.
Using the same ELISA setup, binding of 1 mg/mL biotinylated FH or
recombinant human FHR proteins to anti-FH.07 was measured to
determine cross-reactivity of anti-FH.07.
Generation of Fab9 fragments
Intact mAbs (1 mg/mL in 0.1 M citrate buffer, pH 3.7) were
incubated with pepsin (20 mg/mL, P-6887; Sigma-Aldrich) for
16 hours at 37°C. Next, 3 M NaCl and 1 M Tris were added and pH
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adjusted to 8.9. Remaining intact mAbs and/or Fc fragments were
removed with a protA column. (Fab9)2 fragments were reduced
with 10 mM dithioerythritol for 1 hour and incubated with 20 mM
iodoacetamide. Fab9 fragments were dialyzed to PBS, and cleavage
efficiency was checked on sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Fab9 fragment concentration
was determined at OD280nm using a standard extinction coefficient
(14, 1% wt/vol solution).
C3 deposition on zymosan and LPS
Polysorp 96-well microtiter plates (Nunc) were coated with
zymosan A (100 mg/mL, Z4250; Sigma-Aldrich) or lipopolysaccha-
ride (LPS; 40 mg/mL, L-6386; Sigma-Aldrich) in PBS overnight at
room temperature. After washing with PBS containing 0.1%
(wt/vol) Tween-20, 10% (vol/vol) NHS was incubated in Veronal
buffer (VB; 3 mM barbital, 1.8 mM sodium barbital, and 145 mM
NaCl, pH 7.4) containing 0.05% (wt/vol) gelatin, 5 mM MgCl2,
10 mM EGTA, and 0.1% (wt/vol) Tween-20 with anti-FH mAbs or
isotype controls as indicated. C3b was detected with biotinylated
mAb anti-C3.19 (0.55 mg/mL in HPE) followed by incubation with
0.01% (vol/vol) strep-poly-HRP, in HPE for 1 hour. The ELISA was
developed as previously described.
Cofactor activity assay and C3b/c ELISA
FH cofactor activity was determined as described previously,36 with
some adjustments. Amix of 3mgC3b, 200 ng FH, and 90 ng FI in a total
volume of 20 mL was used. FH was incubated with anti-FH mAbs
(800 ng) in a total volume of 12.5mL for 15minutes at room temperature
prior to adding FI and C3b. Degradation of C3b was visualized by
SDS-PAGE under reducing conditions and stained with PageBlue
Protein Staining Solution (ThermoFisher Scientific). C3b/c levels follow-
ing incubation of NHS (10%, vol/vol) with 50 mg/mL of the indicated
mAbs for 45 minutes were measured as described previously.37
SPR
Surface plasmon resonance (SPR) experiments were performed at
25°C using a flow rate of 15 mL/min and PBS, pH 7.4, with 0.01%
(wt/vol) Tween-20 unless stated otherwise, using a BiaCore T200
and CM5 sensor chips (GE Healthcare).
Affinity of anti-FH.07. RM-19 (20 mg/mL in 10 mM sodium
acetate, pH 5.0) was immobilized at a density of 4000 response units
(RUs) using standard amine coupling. Flow cells were activated for
7 minutes with a 1-to-1 mixture of 0.1 M N-hydroxysuccinimide with
0.1 M 3-(N,N-dimethylamino) propyl-N-ethylcarbodiimide at 5 mL/min
and blocked with 1 M ethanolamine, pH 8.0, for 7 minutes. Anti-FH.07
(30 mg/mL) was captured on 1 flow cell during 60 seconds (80 RUs).
After a stabilization period (60 seconds), duplicate injections, in
random order, of FH (155 kDa, .97% pure) or FH18-20 (21.4 kDa,
.99% pure) were injected (600 seconds) over both flow cells with
twofold decreasing concentrations starting at 200 and 150 nM,
respectively. Dissociation was allowed for 600 seconds. Surfaces
were regenerated with 100 mMH3PO4 at 30mL/min (5 seconds), and
the process was repeated starting with capturing anti-FH.07.
Binding to C3b, iC3b, and C3d. Purified C3b (2045 RUs),
iC3b (2039 RUs), or C3d (2055 RUs) was immobilized using
standard amine coupling as described above, leaving 1 flow cell
as reference for background subtraction. Duplicate injections, in
random order, of FH with twofold decreasing concentrations
starting at 2 mMwere injected at 10mL/min and allowed to associate
and dissociate for 60 seconds. Surfaces were regenerated with 1 M
NaCl at 10 mL/min (10 seconds). To assess the effect of anti-FH.07,
a surplus of anti-FH.07 Fab9 fragments (4 mM) was added. Data
were corrected for the molecular weight of FH (155 kDa) and the
FH:anti-FH.07 Fab9 fragment complex (205 kDa) and analyzed
using Scrubber (v2.0c, BioLogic)
ES and ER hemolytic assay
FH function was determined with a hemolytic assay as described
previously,29 with some adjustments. Prediluted human serum,
either from healthy donors or aHUS patients, was mixed in a 1:1
ratio with ES to reach the indicated final concentrations and 1.053
108 cells/mL in VB with 5 mM MgCl2 and 10 mM EGTA (VB1
EGTA), or VB with 10 mM EDTA as blank, followed by incubation
at 37°C for 75 minutes while shaking. Lysis was stopped with
100 mL ice-cold VB with 20 mM EDTA followed by centrifugation
(2.5 minutes, 471 relative centrifugal force, 7°C). Supernatants were
measured at OD412nm, corrected for background absorbance at
OD690nm and expressed as percentage of the 100% lysis control
(ES incubated with 0.6% [wt/vol] saponin). In follow-up experiments,
20% (vol/vol) human serum was incubated with the indicated mAbs
prior to mixing it at a 1:1 ratio with ES. ER, corresponding to an
OD412nm absorbance of 2.00 (corrected for background absorbance
at OD690nm) at 100% lysis, were incubated with 10% (vol/vol) NHS
and anti-FH.07 or eculizumab at indicated concentrations in VB1
EGTA, in a final volume of 100 mL, at 37°C for 1 hour. After incubation,
100mL VBwas added, followed by centrifugation (1.5 min, 654 relative
centrifugal force, 4°C). Hemolysis was measured as described above.
Fluorescent imaging of C3b deposition on HUVECs
Confluent human umbilical vein endothelial cells (HUVECs; Lonza)
were seeded onto 0.1% (wt/vol) gelatin-coated coverslips (Thermo-
Fisher Scientific) in EMB-plus medium with EGM-plus SingleQuots
(Lonza) at 37°C, 5% CO2 overnight. Before each experiment, the
medium was refreshed and cells were rested for 1 hour. NHS,
“aHUS-like” NHS (containing anti-FH.09) or aHUS-patient sera,
preincubated with anti-FH.07 or isotype control for 15 minutes,
were added (final concentrations: 10% [vol/vol] serum, 10 mg/mL
anti-FH.09, and 75 mg/mL anti-FH.07 or isotype ctrl) and incubated
for 1 hour at 37°C, 5% CO2. Cells were fixed (3% [wt/vol]
paraformaldehyde [Merck Millipore] in PBS containing 1 mM CaCl2
and 0.5 mM MgCl2) for 10 minutes followed by washing and
blocking with 2% (wt/vol) BSA in PBS for 15 minutes. Cells were
stained in PBS, 0.5% (wt/vol) BSA (PB) with 1.25 mg/mL
biotinylated WGA (Vector Laboratories) for 45 minutes, washed
with PB, and stained with 0.004% (vol/vol) Hoechst (ThermoFisher
Scientific), 5.8 ng/mL fluorescein isothiocyanate–labeled anti-
C3.1937,38 and 1% (vol/vol) allophycocyanin-conjugated strepta-
vidin (BD Biosciences) in PB for 30 minutes. Cells were washed
in PBS and mounted with 10% (vol/vol) Mowiol 4-88 (Merck
Millipore), 2.5% (vol/vol) Dabco 33LV (Sigma Aldrich), and 25%
(wt/vol) glycerol, pH 8.5, onto microscope slides. Cells were
imaged with a confocal microscope (403 oil-immersion lens,
LSM510 META; Carl Zeiss MicroImaging). A widefield microscope
(Axio Upright Examiner.Z1, Carl Zeiss MicroImaging) imaging an
area of 103 10 frames and a stack of 15 to 25 layers per coverslip
(403 water lens) was used to quantify C3b deposition. A maximum
intensity projection was composed per coverslip to determine the
mean fluorescence intensity of C3b deposition using ZEN version
2.3 (Carl Zeiss).
26 FEBRUARY 2019 x VOLUME 3, NUMBER 4 ENHANCING FACTOR H RESTORES COMPLEMENT REGULATION 623
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/3/4/621/1631147/advances025692.pdf by R
AD
BO
U
D
 U
N
IVER
SITEIT N
IJM
EG
EN
 user on 26 June 2020
Serum bactericidal activity assay
The bactericidal activity of NHS in the presence of anti-FH.07 or
eculizumab was determined as described previously.38,39 One Shot
TOP10F9 Escherichia coli (ThermoFisher Scientific) carrying the
pcDNA3.1 vector (Invitrogen) were grown in lysogeny broth (LB)
medium containing 50 mg/mL carbenicillin to mid-log, diluted to
OD600 5 0.001 in LB medium, and incubated with 75% (vol/vol)
NHS or HI-NHS, in a final volume of 100 mL, at 37°C for 1 hour while
shaking. Prior to incubation, eculizumab or anti-FH.07 was added to
NHS as indicated. Undiluted up to 104-fold diluted (in LB) culture
(25 mL) was plated on LB with 50 mg/mL carbenicillin agar and
incubated at 37°C overnight to count colony-forming units (CFUs).
The lower detection limit was 40 CFUs/mL. Survival ofNmeningitidis
serogroup B and serogroup W clinical isolates, with eculizumab
or anti-FH.07, was determined as described above using OD530,
TSB-medium, and chocolate agar plates without antibiotic, diluting
the cultures up to 106-fold for CFU counting, and growing the
cultures at 37°C with 5% CO2.
Statistical analysis
Analysis and statistical tests were performed using GraphPad Prism
version 6.04 (GraphPad Software).
Results
Anti-FH.07 inhibits AP complement activation
We obtained 21 mouse mAbs, designated anti-FH.01 to anti-FH.21,
against plasma-derived human FH. Based on the competition
for binding to FH, the mAbs were subdivided into 9 groups
(a representative of each group is shown in Table 1). Epitope
locations were successfully mapped for 8 groups, revealing most
mAbs bound FH at its C-terminal CCP domains. All mAbs binding to
N-terminal epitopes of FH also recognized the splice variant FHL-1,
while all mAbs directed against FH domains 18 to 20 bound with
FHR-1. All mAbs were tested in standard AP complement activation
assays to investigate their effect on complement regulation either
by determining C3b deposition on activating surfaces or by using a
hemolytic assay (Figure 1A-B; supplemental Figure 1). Most mAbs
increased C3b deposition during incubation of 10% (vol/vol) NHS on
either immobilized zymosan or lipopolysaccharide (represented by
anti-FH.09 in Figure 1A-B). One mAb, anti-FH.07 (binding to CCP18
of FH; supplemental Figure 2A-B), decreased C3b deposition on
both surfaces in a dose-dependent manner. This inhibition was
also achieved with Fab9 fragments of anti-FH.07 (50% inhibitory
concentration [IC50] 5 0.102 6 0.046 mM), although intact anti-
FH.07 seemed more potent (IC505 0.0466 0.011 mM; Figure 1C).
This difference in IC50 values likely reflects the presence of 2 antigen-
binding sites in intact IgG compared with one in the Fab9 fragment.
Fluid phase regulation of complement activation prevents C3 ac-
tivation and consumption, which would otherwise decrease functional
C3 levels. To investigate the possibility that anti-FH.07 decreased
complement deposition through increased C3 consumption in fluid
phase, we determinedwhether anti-FH.07 affected the cofactor activity
of FH for FI (Figure 1D). In these experiments, anti-FH.07 was
compared with anti-FH.11. Anti-FH.11 binds an epitope in the first 4
CCP domains of FH, which are essential for cofactor activity. Addition
of anti-FH.11 blocked C3b a9-chain degradation. Addition of anti-
FH.07 did not decrease a9-chain degradation, indicating anti-FH.07
does not inhibit the cofactor activity of FH. Next, we measured fluid
phase C3b, iC3b, and C3c (further abbreviated to C3b/c) levels in
NHS following incubation with anti-FH.07. Increased levels of C3b/c
reflect consumption of C3 due to complement activation or decreased
fluid phase regulation.37 As expected, incubating NHS with anti-FH.11
significantly increased C3b/c levels (P, .0001), which is comparable
to the C3b/c levels resulting from FH depletion (Figure 1E). However,
C3b/c levels remained at background level after incubation with anti-
FH.07. Taking these experiments together, the results show that anti-
FH.07 does not inhibit the cofactor activity of FH but decreases
complement activation on surfaces in another FH-dependent manner.
We assessed the binding affinity of anti-FH.07 for FH by SPR. Full-
length FH was bound by immobilized anti-FH.07 (equilibrium dissoci-
ation constant [KD] 5 5.02 3 10
29 M; Figure 1F), but the curves
fitted poorly to a 1:1 binding model. This might be caused by the
presence of various conformations of FH, which possibly bind
differently to anti-FH.07. To circumvent this, we also determined the
binding of a FH fragment consisting of CCP18 to 20 (FH18-20) to
anti-FH.07. Within this triple-domain construct, the anti-FH.07
epitope is assumed to be freely accessible and not obscured by the
conformation of full-length FH. Indeed, using FH18-20 resulted in
binding curves fitting well to a 1:1 binding model and revealed a
higher affinity of anti-FH.07 for CCP18 than that found for full-length
FH (KD 5 0.36 3 10
29 M; Figure 1G).
Table 1. Mouse mAbs directed against FH used in this study
Designation Isotype Epitope location (CCP domain)* Cross-reactivity Functional effect†
Anti-FH.02 Mouse IgG1, k 20 FHR-1 Strong inhibition
Anti-FH.03 Mouse IgG1, k Unknown FHL-1 Weak inhibition
Anti-FH.07 Mouse IgG1, k 18 FHR-1 Potentiation
Anti-FH.09 Mouse IgG1, k 6 FHL-1, FHR-3, FHR-4A Strong inhibition
Anti-FH.10 Mouse IgG1, k 20 FHR-1 Strong inhibition
Anti-FH.11 Mouse IgG2a, k 1-4 FHL-1 Strong inhibition‡
Anti-FH.15 Mouse IgG1, k 5 FHL-1 Strong inhibition
Anti-FH.16 Mouse IgG1, k 16-17 None Weak inhibition
Anti-FH.19 Mouse IgG1, k 20 FHR-1 Strong inhibition
*Epitope location of each mAb was mapped by determining reactivity to FH fragments (supplemental Figure 2).
†Effect of mAbs on FH function was assessed with standard AP activation assays (see Figure 1A-B; supplemental Figure 1).
‡Anti-FH.11 inhibits the cofactor activity of FH.
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FH binding to C3b is enhanced by anti-FH.07
Next, we investigated by SPR whether the improved surface regulation
of FH induced by anti-FH.07 Fab9 fragments involved the binding of FH
to C3b. The C3b degradation fragments iC3b and C3d were included
as controls, and FH normally shows very low binding to these
fragments.40 As expected, clear binding of FH to C3b was observed,
whereas binding to iC3b and C3d was very limited (Figure 2A, 2B,
and 2C, respectively). Upon addition of Fab9-fragments of anti-FH.07,
binding to C3b greatly increased (Figure 2A), which remained apparent
after correcting for the increasedmolecular weight of the FH:anti-FH.07
complex compared with FH alone (205 kDa vs 155 kDa, respectively).
A similar increase in binding was observed for iC3b and C3d
(Figure 2B-C). Considering the role of C3b within the complement
cascade, it seems likely that the increased binding of FH to C3b in the
presence of anti-FH.07 is involved in the potentiation of FH activity.
Complement regulation in aHUS patient sera is
restored by anti-FH.07
ES express polyanionic molecules similar to those present on
human cells that bind FH and thereby provide a well-known model
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Figure 1. Effect of anti-FH.07 on in vitro AP complement activation. (A) AP-mediated C3b deposition on immobilized zymosan incubated with 10% (vol/vol) NHS in the
presence of anti-FH.07 (binding CCP18) or anti-FH.09 (binding CCP6), as determined by ELISA. C3b deposition without addition of mAbs was set to 100%. (B) As in panel
A, but with immobilized LPS instead of zymosan. (C) IC50 of intact or Fab9 fragments of anti-FH.07 in the AP-mediated C3b deposition assay on immobilized LPS. (D) Fluid
phase regulation by FH was assessed with a fluid phase cofactor activity assay. Purified C3b was incubated with FH and FI, with addition of the indicated mAbs (anti-FH.11
binds CCP1-4). Cleavage of the a9-chain of C3b was visualized with SDS-PAGE run under reducing conditions, stained with PageBlue. Lanes were run on the same gel
but were noncontiguous. (E) C3b/c concentration determined by ELISA after incubation of NHS with the indicated mAbs to assess fluid phase activation of C3. (F-G)
Representative SPR sensograms (n 5 2) of the binding of full-length FH (F) or a fragment of FH comprised of domains 18 to 20 (G) to immobilized anti-FH.07. For full-length
FH, a twofold diluting concentration range starting at 200 nM was probed. For FH18-20, a twofold diluting concentration range starting at 150 nM was probed. Injections were
done in random order. The first 200 seconds of the 600-second dissociation phase are shown. Red lines depict the fits of a 1:1 association model. Data in panels A-C,E are
presented as mean of n 5 3 with standard deviation. ****P , .0001, 1-way ANOVA. ns, not significant; RT, room temperature.
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to study FH function on human-like cell surfaces.33 ES are lysed
when incubated with human serum with impaired FH function. We
obtained pretreatment serum from 11 aHUS patients with unique
heterozygous mutations in FH (Figure 3A). This allowed us to test
the effect of anti-FH.07 on complement-mediated lysis of ES caused
by impaired FH-mediated complement regulation. ES were lysed in
a dose-dependent manner when incubated with aHUS#1 serum
carrying a heterozygous FH mutation in domain 20 (S1191L)
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Figure 2. Effect of anti-FH.07 Fab9 fragment on binding of FH to C3 fragments. Binding of FH in the absence or presence of anti-FH.07 to C3b (A), iC3b (B), and
C3d (C). C3b (2,045 RU), iC3b (2,039 RU) and C3d (2,055 RU) were amine-coupled to a CM5 chip to assess binding of FH (black lines) or FH in the presence of 4 mM
anti-FH.07 Fab9 fragments (FH:07, orange lines). Double injections of a twofold diluting concentration range starting at 2 mM FH were probed in random order throughout.
For ease of interpretation, only the sensograms of 2, 1, and 0.5 mM FH and FH:07 are shown. Sensograms were normalized for the molecular weight of FH (155 kDa) or the
FH:anti-FH.07 Fab9 fragment complex (205 kDa), respectively. All graphs shown are representative of multiple experiments (n $ 2).
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Figure 3. Anti-FH.07 restores complement regulation in aHUS patient serum on ES. (A) Schematic representation of the 20 CCP domains of FH with the location of
the heterozygous mutations of each of the aHUS patients (numbered 1 to 11), as well as the domain targeted with anti-FH.07. (B) Incubation of ES with serum from an aHUS
patient carrying a heterozygous mutation in CFH (n 5 2) or a serum pool from healthy individuals (NHS pool, n 5 3). Hemolysis was measured at 412 nm and corrected for
background at 690 nm. The hemolysis observed by incubation of ES with 0.6% (wt/vol) saponin was set to 100%. (C) Addition of anti-FH.07 or an isotype control to 10% (vol/vol)
serum of aHUS #1 or a NHS pool (n 5 4). (D) Hemolysis observed in 11 aHUS sera (10%, vol/vol) with different CFH mutations before and after addition of anti-FH.07 or an
isotype control; numbers correspond to the aHUS patient number in panel A. Addition of EDTA serves as the negative control of ES lysis. Each point represents the mean of
duplicates of a single experiment, and red lines indicate overall mean with standard deviation. (E) Comparison of the effect intact IgG and Fab9 fragments from a control
IgG mAb and anti-FH.07 in the ES hemolytic assay performed with 10% (vol/vol) aHUS#1 serum. Data in panels C-E are presented as mean with standard deviation.
*P , .05, ****P , .0001, 2-way ANOVA.
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(Figure 3B). In contrast, incubation with a NHS pool containing fully
functional FH resulted in 20% lysis. Addition of anti-FH.07 to
aHUS#1 serum significantly decreased complement-mediated ES
hemolysis (P , .0001; Figure 3C). In fact, anti-FH.07 was also
effective in NHS, reducing the relatively low background ES
hemolysis from 27% to 10% (P , .05). Anti-FH.07 was further
tested with other aHUS sera. Despite variation in ES hemolysis
between the different aHUS sera, anti-FH.07 decreased lysis to
background levels in all sera (Figure 3D). As expected,33 mutations
located in CCP18-20 of FH caused medium to high ES hemolysis,
but hemolysis was likely also influenced by individual variation
in total complement activity of each aHUS serum. In line with the
previous experiments, anti-FH.07 Fab9 fragments prevented ES
hemolysis in aHUS#1 serum (Figure 3E).
Anti-FH.07-mediated protection is independent of
FHR-1 and surface specific
To further investigate the effect of anti-FH.07 on ES hemolysis, and
because aHUS sera are limiting both in availability and complement
activity, we developed an induced ES hemolytic assay using NHS
in which FH was inhibited with anti-FH.09. Addition of 0.067 mM
(10 mg/mL) anti-FH.09% to 10% (vol/vol) NHS resulted in 87%
ES hemolysis, similar to the aHUS sera (Figure 4A). Anti-FH.07
completely prevented the induced ES hemolysis (Figure 4B). This
assay allows for the investigation of the complement-inhibiting
activity of anti-FH.07 under more controlled conditions and com-
paring it with eculizumab (Figure 4C). Eculizumab inhibited ES
lysis with an IC50 of 0.015 mM, whereas the IC50 of anti-FH.07 is
0.082 mM (Figure 4D).
As previously mentioned, anti-FH.07 binds to CCP18 of FH, which is
highly similar to CCP3 of FH-homolog FHR-1. Like all FH-related
proteins, FHR-1 contains CCP domains similar to the C3b binding
CCP domains of FH.41 As anti-FH.07 cross-reacts with FHR-1
(supplemental Figure 2C), it is possible that the protective effect of
anti-FH.07 is due to FHR-1 instead of FH. Therefore, we investigated
whether in the absence of FHR-1, anti-FH.07 still protects ES. We
induced ES hemolysis in a serum pool from 4 healthy donors previously
typed as FHR-1 deficient due to the homozygous CFHR3/CFHR1
deletion (CFHR12/2 pool).35 Without FHR-1, anti-FH.07 still pre-
vented ES hemolysis (Figure 4D; supplemental Figure 3A-B).
Eculizumab was equally effective in the NHS pool and the
CFHR12/2 pool, whereas anti-FH.07 was more effective in the
CFHR12/2 pool (IC50 5 0.067 mM, P , .05), suggesting that a
small portion of anti-FH.07 added to the NHS pool bound to FHR-
1. More importantly, these results show that FHR-1 is not involved
in the protective effect of anti-FH.07.
In contrast to ES, ER lack polyanionic residues that bind human FH
and are lysed when incubated with NHS. ER were used to
investigate whether anti-FH.07 confers FH-mediated regulation to
cells that normally are not effectively protected against human
complement. ER remained fully susceptible to AP-mediated hemoly-
sis even in the presence of high amounts of anti-FH.07, whereas
eculizumab inhibited ER hemolysis, with an IC50 of 0.008 mM
(Figure 4E). These results indicate that anti-FH.07-potentiated FH still
requires polyanionic residues to bind cells. The observed increased
binding of FH to C3b due to anti-FH-07 does not overcome this
crucial function of FH in distinguishing human(-like) surfaces from
nonhuman surfaces.
Complement activation on human cells is inhibited
by anti-FH.07
Next, we determined whether impaired complement regulation on
human cells was also restored by anti-FH.07. The aHUS-like
NHS pool, in which FH was partially inhibited with anti-FH.09, was
used to induce complement activation on HUVECs. Incubation of
HUVECs with NHS did not result in any significant C3b deposition,
although overall relative C3 deposition levels seemed somewhat
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Figure 4. Anti-FH.07 protects ES from induced complement-mediated
hemolysis. (A) ES hemolysis was induced in 10% (vol/vol) NHS by inhibiting FH with
anti-FH.09 (n 5 3). Hemolysis was measured at 412 nm and corrected for background
at 690 nm. The hemolysis observed by incubation of ES with 0.6% (wt/vol) saponin
was set to 100%. (B) Titration of anti-FH.07 in the induced ES hemolysis assay
(n 5 3). For this ES hemolytic assay, 0.067 mM (10 mg/mL) anti-FH.09 was used,
resulting in 87% ES lysis as indicated with the dashed lines in panel A. (C) Comparison
of the inhibitory effect of anti-FH.07 and eculizumab in the ES hemolytic assay
performed in panel B (after normalization). Dashed line indicates 50% of the normalized
ES hemolysis. (D) IC50 values of anti-FH.07 and eculizumab in the induced ES
hemolytic assay as in panel C (n 5 3) using either a NHS pool or a pool of sera from
4 healthy donors lacking the CFHR1 gene (CFHR12/2 pool). (E) Incubation of ER
with 10% (vol/vol) NHS serum in the presence of eculizumab or anti-FH.07 at the
indicated concentrations (n 5 2). All data are presented as mean with standard
deviation. *P , .05, ****P , .0001, 2-way ANOVA.
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higher compared with HI-NHS (Figure 5A-B). C3b deposition was
greatly increased with aHUS-like NHS (Figure 5A-B). This was
completely prevented by anti-FH.07 (P , .05), restoring C3b
deposition to background levels. Having established a HUVEC-
based FH functional assay, C3b deposition using 5 aHUS sera was
determined. Incubation of HUVECs with aHUS sera resulted in
clear C3b deposition (Figure 5C). Anti-FH.07 prevented C3b
deposition in all aHUS sera, independent of the FH mutation.
Anti-FH.07 allows normal complement-mediated
bacterial killing
A well-known adverse side effect of eculizumab treatment is the
increased risk for N meningitidis infections by inhibiting complement-
mediated lysis. To examine whether anti-FH.07 affected complement-
mediated killing of bacteria, the bactericidal activity of NHS against
E coli andNmeningitidis in the presence of anti-FH.07 or eculizumab
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Figure 5. Anti-FH.07 increases complement regulation on human cell surfaces. (A) Immunofluorescent imaging of C3b deposition on HUVECs incubated with 10%
(vol/vol) NHS, HI-NHS, or aHUS-like NHS in the absence or presence of anti-FH.07. For each condition, a representative image of independent experiments (n 5 3) is shown.
(B) Relative C3b deposition on HUVECs (from panel A), calculated by quantifying the mean fluorescence intensity (MFI) using a maximum intensity projection of the whole coverslip
(10 3 10 3 15 images per coverslip). Anti-C3.19 MFI of NHS was set to 1. Bars represent mean with standard deviation (n 5 3). (C) Immunofluorescent imaging of C3b deposition on
HUVECs following incubation with 10% (vol/vol) serum of 5 aHUS patients in the absence of presence of an isotype control mAb or anti-FH.07. In panels A,C, HUVECs were stained
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was tested. E coliwere killed in NHS, while HI-NHS did not show any
bactericidal activity (Figure 6A). As expected, eculizumab prevented,
in a dose-dependent manner, the killing of E coli in NHS. In contrast,
complement-mediated killing of E coli remained fully intact when
anti-FH.07 was added (P , .0001). Similar results were obtained
with both N meningitidis serogroup B and W (Figure 6B). Again,
eculizumab promoted survival, whereas anti-FH.07 did not affect
killing of N meningitidis serogroup B (P, .0001) or W (P, .01). Of
note, eculizumab prevented complement-mediated killing of bacteria
at 0.2 mM in 75% (vol/vol) NHS, which is the same ratio as seen
in the ES hemolytic assay in which 0.027 mM in 10% (vol/vol) NHS
was effective. In contrast, anti-FH.07 did not prevent complement-
mediated killing of bacteria at 2.0 mM in 75% (vol/vol) NHS, which
is a twofold higher ratio than the 0.133 mM in 10% (vol/vol) NHS
that was effective in the hemolytic assay.
Discussion
Excessive complement activation on human cells leads to severe
disease, such as aHUS, and there is an increasing interest in
complement targeting therapeutics to resolve this. However, inhibiting
the detrimental effects of complement while preserving the beneficial
protective role against pathogens is an ongoing challenge. Here, we
investigated the possibility of enhancing the endogenous complement
regulator FH and describe a novel approach for inhibiting complement.
We characterized an mAb, designated anti-FH.07, that binds CCP18
of FH and inhibits complement in a FH-dependent manner. Anti-FH.07
preserved the specificity of FH, as potentiation was only observed
on cells already able to bind human FH (ie, ES and HUVECS) and
did not confer FH regulation to bacteria. Thus, we have discovered
a potential novel therapeutic approach for inhibiting complement
activation on human cells while preserving the beneficial protective
role of complement against pathogens.
We ruled out FHR-1 or antibody-mediated dimerization as the
underlying mechanism of action for anti-FH.07 while showing an
increased binding of the FH:anti-FH.07 complex to C3b. We
hypothesize that anti-FH.07 induces an intramolecular conforma-
tional change in FH, transitioning it from a less active conformation
into a more active conformation. Alternatively, anti-FH.07 may lock
FH in its more active conformation when this change is induced by
surface binding. The presence of such a latent conformation of FH
in the circulation has been previously suggested.7 In support of
this, FH constructs that lack the domains suggested to be involved
in the “closed-up” FH conformation (eg, CCP10-15 or CCP6-17)
were shown to be more effective in surface complement regula-
tion than full-length FH.39,42 Other recent research showed that a
truncated form of the major FH-binding protein expressed by
Streptococcus pneumoniae, PspCN, also enhances FH activity,
although it binds to CCP9 and not CCP18.43 Similar to anti-
FH.07, PspCN increased the binding of FH to C3b, iC3b, and
C3d. Possibly, a similar active FH conformational change, as
suggested for the FH:PspCN complex, is induced by anti-FH.07.
A closed-up conformation of full-length FH would also explain the
lower apparent association rate (ka) of full-length FH to anti-FH.07
compared with FH18-20. It seems likely that CCP18 of the FH18-20
fragment is more accessible in comparison with the closed-up full-
length FH molecule. The linker between CCP18 and CCP19 of
FH was reported to be very flexible and contributes to the high
variability in the conformation of the C-terminus, which contains
crucial binding sites for both C3b and polyanions.44 Stabilization
of the activated C-terminal conformation by binding CCP18 with
anti-FH.07 may facilitate interactions with these FH ligands, as
was observed in this study for full-length FH in complex with
anti-FH.07 Fab9 fragments in the interaction with C3b.
We explored anti-FH.07 in a clinically relevant setting using aHUS
patient sera. In all sera tested, anti-FH.07 restored the impaired FH
function caused by heterozygous mutations. We only tested sera
from aHUS patients with heterozygous mutations in the CFH
gene. Testing anti-FH.07 in aHUS patient sera carrying mutations
in C3 or CFB or with autoantibodies against FH would provide
additional insights in the applicability of FH potentiation, but such
samples were unavailable during this study. Our artificial aHUS-
like serum resembles the presence of inhibiting autoantibodies
against FH found in aHUS patients. As anti-FH.07 restored
complement regulation in aHUS-like serum, anti-FH.07 is expected
to also restore complement regulation in aHUS patients with
anti-FH autoantibodies.
We compared anti-FH.07 with eculizumab in several experimen-
tal settings. In vitro hemolytic assays showed that preventing
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Figure 6. Bactericidal activity of NHS remains intact in the presence of anti-FH.07. (A) E coli CFUs/mL were determined after incubation in 75% (vol/vol) NHS, NHS
preincubated with anti-FH.07, NHS preincubated with eculizumab, or HI-NHS. (B) CFUs/mL of 2 clinical isolates of N meningitidis serogroup B (left) and serogroup W (right),
determined after incubation in 75% (vol/vol) NHS, NHS preincubated with anti-FH.07, NHS preincubated with eculizumab, or HI-NHS. All data are presented as mean with
standard deviation (n 5 3). **P , .01, ****P , .0001, 2-way ANOVA.
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complement-mediated lysis requires fivefold less eculizumab
than anti-FH.07, suggesting that enhancing FH activity is less
effective than inhibiting C5. However, the molar concentrations
of the respective targets of eculizumab (C5: 0.4 mM) and anti-
FH.07 (FH: 2.0 mM) differ fivefold in serum. More importantly, we
showed that at eculizumab concentrations (ie, proportional to
serum content) that prevented hemolysis, bacteria were also
protected from complement-mediated killing. In contrast, even
concentrations of anti-FH.07 twofold higher than necessary to
fully protect erythrocytes did not impair complement-mediated
killing of E coli and N meningitidis. This suggests that enhancing
FH activity is a more selective, and thus potentially safer, strategy
in protecting human cells from complement-mediated destruc-
tion than inhibiting C5. We may even speculate on beneficial
effects of enhancing FH function in cases of severe infections or
septicemia in which overwhelming complement activation con-
tributes to vascular damage and organ dysfunction.45 The
complement inhibitory function of FH has previously been used
in the development of therapeutic strategies to inhibit comple-
ment, including the various mini-FH constructs.39,40,42,46-48
TT30, a fusion protein linking the human complement receptor
type 2 (CR2/CD21) C3-fragment binding domain with the
inhibitory domains of FH, has been shown to be highly effective
in preventing AP activation in vitro, including rescuing paroxys-
mal nocturnal hemoglobinuria erythrocytes from lysis.49,50 This
strengthens our notion that increasing the function of endoge-
nous FH with an mAb is beneficial in preventing complement-
mediated damage. Increased regulation of complement may also
be protective in ischemia-reperfusion injury, as often indicated
by the protective effects of complement blockade in various
experimental models to date.51,52
In summary, we demonstrate a novel approach for inhibiting complement
on human cells while preserving the complement-mediated killing of
bacteria. This was achieved by enhancing FH activity through
targeting CCP18 with mAb anti-FH.07. Both erythrocytes and
endothelial cells were protected by anti-FH.07 from complement-
mediated damage, and anti-FH.07 restored the impaired FH
function in aHUS patients with different FH mutations in vitro. Our
results indicate that FH circulates in a less active form, which
switches into a more active conformation by targeting CCP18
with an mAb. As the complement system plays a pivotal role within
our immune system, enhancing FH activity can possibly be used
to restore the balance and limit collateral damage to human cells
whenever excessive complement activation occurs.
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